Vanda Pharmaceuticals Inc. Announces Annual Meeting of Stockholders on May 17, 2024

TL;DR

<b>Vanda Pharmaceuticals Inc. will hold its virtual Annual Meeting of Stockholders on May 17, 2024, to elect directors, ratify auditors, and approve executive compensation.</b>

AI Summary

Vanda Pharmaceuticals Inc. (VNDA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Annual Meeting of Stockholders to be held virtually on May 17, 2024. Proposes election of Mihael H. Polymeropoulos, M.D. and Phaedra S. Chrousos as Class III directors. Seeks ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2024. Requests advisory approval of named executive officer compensation. Proposes approval of an amendment to the Company's compensation policy.

Why It Matters

For investors and stakeholders tracking Vanda Pharmaceuticals Inc., this filing contains several important signals. Stockholders will vote on the election of two Class III directors, Mihael H. Polymeropoulos, M.D. and Phaedra S. Chrousos, whose terms would extend to the 2027 annual meeting. The meeting includes a vote to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.

Risk Assessment

Risk Level: medium — Vanda Pharmaceuticals Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting, which typically involves standard corporate governance matters like director elections and auditor ratification, posing no immediate unusual risks.

Analyst Insight

Stockholders should review the proposed director nominees and executive compensation details before the May 17, 2024, Annual Meeting.

Key Numbers

• May 17, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• 2027 — Director Term End (Year until which proposed directors would serve)
• December 31, 2024 — Fiscal Year End (Fiscal year for which auditor is being ratified)

Key Players & Entities

• Vanda Pharmaceuticals Inc. (company) — Registrant
• Mihael H. Polymeropoulos, M.D. (person) — Proposed Class III director
• Phaedra S. Chrousos (person) — Proposed Class III director
• PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
• May 17, 2024 (date) — Annual Meeting date
• December 31, 2024 (date) — Fiscal year end for auditor ratification

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
• Virtual Meeting Format [low — operational]: Ensuring a smooth and accessible virtual meeting experience for all stockholders is crucial for participation and engagement.
• Auditor Ratification [low — financial]: The ratification of the independent auditor is a standard procedure but essential for financial reporting integrity.

Industry Context

Vanda Pharmaceuticals Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing treatments for central nervous system disorders.

Regulatory Implications

The company is subject to the regulations of the U.S. Securities and Exchange Commission (SEC) concerning public company filings and shareholder communications.

What Investors Should Do

1. Review the biographies and qualifications of the proposed director nominees, Mihael H. Polymeropoulos, M.D. and Phaedra S. Chrousos.
2. Evaluate the company's executive compensation structure and rationale presented in the proxy statement.
3. Confirm the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2024.

Key Dates

• 2024-05-17: Annual Meeting of Stockholders — Key date for voting on proposals and electing directors.

Year-Over-Year Comparison

This is a DEF 14A filing, a proxy statement for the annual meeting, and does not contain comparative financial data from a previous filing.

Key Financial Figures

• $100.0 million — dian rights to PONVORY from Janssen for $100.0 million and the transition is ongoing. Other
• $192.6 million — BUSINESS HIGHLIGHTS Total revenues of $192.6 million for the full year 2023. HETLIOZ net pr
• $100.2 million — ear 2023. HETLIOZ net product sales of $100.2 million for the full year 2023. Fanapt net pro
• $90.9 million — year 2023. Fanapt net product sales of $90.9 million for the full year 2023. PONVORY net pr
• $1.6 million — r 2023. PONVORY net product sales were $1.6 million in the fourth quarter of 2023. These ne
• $388.3 million — quivalents and marketable securities of $388.3 million. Net income of $2.5 million for the fu
• $2.5 million — ities of $388.3 million. Net income of $2.5 million for the full year 2023. 1 Table of Co
• $75,000 — l pay Innisfree an amount not to exceed $75,000 in fees for its proxy solicitation serv

Filing Documents

• ea0204298-01.htm (DEF 14A) — 3216KB
• tbarchart_001.jpg (GRAPHIC) — 315KB
• tbarchart_002a.jpg (GRAPHIC) — 136KB
• tbarchart_002b.jpg (GRAPHIC) — 145KB
• tbarchart_002c.jpg (GRAPHIC) — 142KB
• tbarchart_002d.jpg (GRAPHIC) — 142KB
• tcross.jpg (GRAPHIC) — 2KB
• tick.jpg (GRAPHIC) — 1KB
• tick1.jpg (GRAPHIC) — 1KB
• tpiechart_001.jpg (GRAPHIC) — 247KB
• tproxy_001.jpg (GRAPHIC) — 1029KB
• tproxy_002.jpg (GRAPHIC) — 1156KB
• ttimothy_sig.jpg (GRAPHIC) — 11KB
• 0001213900-24-036802.txt (&nbsp;) — 12136KB
• vnda-20240517.xsd (EX-101.SCH) — 10KB
• vnda-20240517_def.xml (EX-101.DEF) — 8KB
• vnda-20240517_lab.xml (EX-101.LAB) — 32KB
• vnda-20240517_pre.xml (EX-101.PRE) — 10KB
• ea0204298-01_htm.xml (XML) — 384KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 24 EXECUTIVE OFFICERS 26

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 27 PROPOSAL 3: ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION 49 PROPOSAL 4: AMENDMENT TO AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN 50 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 59 OTHER MATTERS 61 NO INCORPORATION BY REFERENCE 61 NOTE ABOUT FORWARD-LOOKING STATEMENTS 61 CONTACT FOR QUESTIONS AND ASSISTANCE WITH VOTING 62 APPENDIX A — 2016 EQUITY INCENTIVE PLAN A-1 i Table of Contents 2024 PROXY STATEMENT — SUMMARY This summary highlights information contained elsewhere in this Proxy Statement and does not contain all of the information you should consider. You should read the entire Proxy Statement carefully before voting . We are making this Proxy Statement, the proxy card and our Annual Report on Form 10 -K for the year ended December 31, 2023 (the "Annual Report") available to stockholders at www.proxyvote.com . On or about April 29, 2024, we will begin mailing to certain of our stockholders entitled to vote at the Annual Meeting our Proxy Statement, proxy card and Annual Report, as well as instructions on how to vote via proxy by mail, telephone, or over the Internet. GENERAL INFORMATION HETLIOZ (tasimelteon) In July 2023, the U.S. Food and Drug Administration ("FDA") accepted our supplemental New Drug Application ("sNDA") for HETLIOZ in the treatment of insomnia for filing and set a Prescription Drug User Fee Act ("PDUFA") target action date of March 4, 2024 for its decision. On March 4, 2024, we received a Complete Response Letter ("CRL") from the FDA as part of the FDA's ongoing review of our sNDA for HETLIOZ in the treatment of insomnia. Fanapt (iloperidone) In August 2023, the FDA accepted our sNDA for Fanapt in bipolar I disorder for adults for filing and set a PDUFA target action date of April 2, 2024 for its decision. On April 2, 2024, the FDA approved Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Tradipita

View Full Filing

View this DEF 14A filing on SEC EDGAR